R. CHRISTIAN B. EVENSEN is the founding and managing partner of Flintridge Capital Investments, an algorithmic trading firm, and Flintridge Capital Technologies, which develops these technologies, located in Glendale, California. Chris has spent the majority of his career structuring corporate investments, real estate investments, and derivatives. He was founder and managing partner of Canyon Partners, an alternative asset manager in equity, bonds, and real estate located in Los Angeles, California. Prior to the formation of Canyon Partners in 1990, Chris was senior vice president of the High Yield Bond Department of Drexel Burnham Lambert and director of the International Markets Group, responsible for the international markets activities of the firm. Prior to 1986, Mr. Evensen worked at Merrill Lynch, First Interstate Limited, and The Bank of New York, where he structured derivatives products and commercial and project loans. Chris is a trustee of Johns Hopkins Medicine, where he is a member of the Finance Committee and Investments Subcommittee. He is a board member of Johns Hopkins Medicine International, which manages the international activities of Johns Hopkins Medicine. He is the chair of the Johns Hopkins Prostate Cancer Advisory Board at the Brady Urological Institute. Chris is also a board member of the Prostate Cancer Foundation, where he is the chair of the Discovery and Translation Committee and the Development Committee, and a board member of the Prostate Cancer Foundation of Norway. He is a former trustee of Chandler School in Pasadena, California, as well as the Los Angeles County Economic Development Corporation. Chris earned a BA in economics with honors from Williams College. He is married to Felicia Evensen, and they are the proud parents of six children.
R. Christian B. Evensen Professorship in Urology at the Brady Urological Institute
School of Medicine
Urology
Established in 2014 by the generosity of R. Christian B. Evensen
Held by Max Kates
MAX KATES, MD, is the R. Christian B. Evensen Professor and an associate professor of urology and oncology at the Brady Urological Institute at Johns Hopkins. He directs the Division of Urologic Oncology for the Brady Urological Institute and is a clinical director of the bladder cancer multidisciplinary clinic. Dr. Kates completed his undergraduate degree at Wesleyan University in Connecticut before pursuing his medical degree at Mount Sinai School of Medicine in New York. He then went on to train at Johns Hopkins for his urologic residency and the Society of Urologic Oncology (SUO) fellowship. Dr. Kates has expertise in all areas of urologic oncology, with a particular clinical emphasis on prostate and bladder cancer and a research interest in novel treatments for cancers of the urinary tract. Dr. Kates has authored more than 135 journal articles in the fields of bladder, prostate, and kidney cancer. He currently has a provisional patent for a novel intravesical chemotherapy developed with nano-engineer collaborators. Dr. Kates has made important discoveries into the mechanism of action of intravesical BCG, the most common treatment for bladder cancer. He is the principal investigator on multiple trials and is currently leading EA8212 BRIDGE, a randomized trial open in over 150 centers in the United States comparing BCG to GemDoce chemotherapy for early-stage bladder cancer.